Abstract: Verified transactions through integrations of social network and payment service computing platforms are described. A payment service computing platform may determine a relationship between one or more users and a first user based on interaction data, and, in response to an interaction with a first interactive element corresponding to a second user, cause display of a second asset profile of the second user and a second interactive element to request to purchase assets that correspond to an allocation of a set of assets owned by the second user. The payment service computing platform may further receive a request to purchase a subset of the set of assets based on an interaction with the second interactive element, determine units for each of the assets to be purchased in accordance with a specified value amount, and assign ownership interest of the units to an account associated with the first user.

Abstract: Verified transactions through integrations of social network and payment service computing platforms are described. A payment service computing platform may generate a token associated with a first account associated with a payment service, the token being configured to facilitate a number of transfers of an amount from the first account to one or more second accounts. The payment service computing platform may further receive a first request, from an electronic device of a second user associated with the one or more second accounts, to redeem the amount associated with the token, facilitate acquisition of one or more assets for the second user, wherein the one or more assets are determined by the second user or based at least in part on a machine-learning model trained to infer a preference of the first or second user, and associate the one or more assets with a second account of the second user.

Abstract: The invention provides compounds of formula I: and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula I: and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I) and salts thereof wherein R4-R8 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I) and salts thereof wherein R4-R8 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.